Aztreonam is a monobactam antibiotic specifically designed to target Gram-negative bacteria, offering a unique mechanism of action that minimizes the risk of cross-resistance with other beta-lactam antibiotics. It is particularly effective against Pseudomonas aeruginosa, making it a critical option in the treatment of infections in patients with cystic fibrosis or those who are immunocompromised.